Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome.
Przegl Lek
; 74(4): 144-6, 2017.
Article
em En
| MEDLINE
| ID: mdl-29696950
ABSTRACT
Introduction:
The aim of our study was to assess the values of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides before and after treatment with metformin in lean patients with polycystic ovary syndrome (PCOS). Material andMethods:
32 patients received metformin 1500 mg per day in three divided doses. Lipids measurements were performed twice before and after 6 months of treatment with metformin.Results:
In lean patients with PCOS after treatment with metformin we observed statistically significant lower LDL-C levels (4.16±0.79 mmol/l vs 3.4±0.86 mmol/l, p<0.05) and triglycerides levels (1.8±0.53 mmol/l vs 1.12±0.64 mmol/l, p<0.05). We observed an increase in HDL values and a decrease in total cholesterol values, but these changes were not statistically significant (1.5±0.71 mmol/l vs 1.71±0.69 mmol/l, p=0.09; 5.87±0.92 mmol/l vs 5.69±0.97 mmol/l, p=0.11).Conclusion:
Our study showed that treatment of 1500 mg metformin for about six months among PCOS women results in an improvement in serum lipid profiles. We observed a significant decrease in LDL-C and triglycerides values after metformin therapy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Síndrome do Ovário Policístico
/
Lipídeos
/
Metformina
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article